\BOOKMARK [1][-]{Doc-Start}{Acknowledgments}{}% 1
\BOOKMARK [1][-]{Doc-Start}{Abstract}{}% 2
\BOOKMARK [1][-]{Doc-Start}{Resumen}{}% 3
\BOOKMARK [1][-]{Doc-Start}{Preface}{}% 4
\BOOKMARK [1][-]{Doc-Start}{Index of figures}{}% 5
\BOOKMARK [1][-]{Doc-Start}{List of tables}{}% 6
\BOOKMARK [1][-]{Doc-Start}{List of publications}{}% 7
\BOOKMARK [1][-]{Item.6}{Introduction}{}% 8
\BOOKMARK [2][-]{subsection.1.1.1}{Protein are essential molecules}{Item.6}% 9
\BOOKMARK [3][-]{subsubsection.1.1.1.1}{Protein structure}{subsection.1.1.1}% 10
\BOOKMARK [3][-]{subsubsection.1.1.1.2}{Protein Structure Determination}{subsection.1.1.1}% 11
\BOOKMARK [3][-]{subsubsection.1.1.1.3}{Protein Structure Prediction}{subsection.1.1.1}% 12
\BOOKMARK [3][-]{subsubsection.1.1.1.4}{Homology modeling}{subsection.1.1.1}% 13
\BOOKMARK [3][-]{subsubsection.1.1.1.5}{Protein function}{subsection.1.1.1}% 14
\BOOKMARK [3][-]{subsubsection.1.1.1.6}{Protein-Ligand Interactions}{subsection.1.1.1}% 15
\BOOKMARK [3][-]{subsubsection.1.1.1.7}{Protein-ligand binding energetics}{subsection.1.1.1}% 16
\BOOKMARK [3][-]{subsubsection.1.1.1.8}{Protein-ligand prediction}{subsection.1.1.1}% 17
\BOOKMARK [3][-]{subsubsection.1.1.1.9}{Comparative docking approach}{subsection.1.1.1}% 18
\BOOKMARK [2][-]{subsection.1.1.2}{Drug discovery}{Item.6}% 19
\BOOKMARK [3][-]{subsubsection.1.1.2.1}{Computational drug discovery}{subsection.1.1.2}% 20
\BOOKMARK [2][-]{subsection.1.1.3}{Drug discovery in Tuberculosis}{Item.6}% 21
\BOOKMARK [3][-]{subsubsection.1.1.3.1}{Research strategies against MTB.}{subsection.1.1.3}% 22
\BOOKMARK [3][-]{subsubsection.1.1.3.2}{In-silico approaches in TB}{subsection.1.1.3}% 23
\BOOKMARK [2][-]{subsection.1.1.4}{Targeted cancer therapy}{Item.6}% 24
\BOOKMARK [3][-]{subsubsection.1.1.4.1}{Monoclonal antibodies}{subsection.1.1.4}% 25
\BOOKMARK [3][-]{subsubsection.1.1.4.2}{Small molecule kinase inhibitors}{subsection.1.1.4}% 26
\BOOKMARK [3][-]{subsubsection.1.1.4.3}{Resistance to targeted cancer therapies}{subsection.1.1.4}% 27
\BOOKMARK [2][-]{subsection.1.1.5}{Motivation}{Item.6}% 28
\BOOKMARK [1][-]{section.1.2}{Objectives}{}% 29
\BOOKMARK [1][-]{section.1.3}{Results}{}% 30
\BOOKMARK [2][-]{subsection.1.3.1}{Ligand-Target Prediction by Structural Network Biology using nAnnolyze}{section.1.3}% 31
\BOOKMARK [2][-]{subsection.1.3.2}{Target Prediction for two Open Acess Sets of Compounds Active against Mycobacterium tuberculosis}{section.1.3}% 32
\BOOKMARK [2][-]{subsection.1.3.3}{Rational design of non-resistant targeted cancer therapies}{section.1.3}% 33
\BOOKMARK [1][-]{section.1.4}{Discussion}{}% 34
\BOOKMARK [2][-]{subsection.1.4.1}{nAnnolyze: predicting large scale and structurally detailed ligand-target interaction using a network-based representation}{section.1.4}% 35
\BOOKMARK [3][-]{subsubsection.1.4.1.1}{Main findings}{subsection.1.4.1}% 36
\BOOKMARK [3][-]{subsubsection.1.4.1.2}{Impact of the presented research}{subsection.1.4.1}% 37
\BOOKMARK [3][-]{subsubsection.1.4.1.3}{Limitations}{subsection.1.4.1}% 38
\BOOKMARK [3][-]{subsubsection.1.4.1.4}{Future perspectives}{subsection.1.4.1}% 39
\BOOKMARK [2][-]{subsection.1.4.2}{Target prediction for two set of compounds active against MTB}{section.1.4}% 40
\BOOKMARK [3][-]{subsubsection.1.4.2.1}{Main findings}{subsection.1.4.2}% 41
\BOOKMARK [3][-]{subsubsection.1.4.2.2}{Impact of the presented research}{subsection.1.4.2}% 42
\BOOKMARK [3][-]{subsubsection.1.4.2.3}{Limitations}{subsection.1.4.2}% 43
\BOOKMARK [3][-]{subsubsection.1.4.2.4}{Future perspectives}{subsection.1.4.2}% 44
\BOOKMARK [2][-]{subsection.1.4.3}{Rational design of non-resistant targeted cancer therapies}{section.1.4}% 45
\BOOKMARK [3][-]{subsubsection.1.4.3.1}{Main findings}{subsection.1.4.3}% 46
\BOOKMARK [3][-]{subsubsection.1.4.3.2}{Impact of the presented research}{subsection.1.4.3}% 47
\BOOKMARK [3][-]{subsubsection.1.4.3.3}{Limitations}{subsection.1.4.3}% 48
\BOOKMARK [3][-]{subsubsection.1.4.3.4}{Future perspectives}{subsection.1.4.3}% 49
\BOOKMARK [1][-]{section.1.5}{Conclusions}{}% 50
